Excellence in ScreeningWe are committed to delivering innovations in cervical cancer screening so that you can provide the best possible care for your patients.

  • Both Pap and HPV testing remain critical components of cervical cancer screening, with current studies supporting the continued importance of the Pap test in accurately identifying ≥CIN3 and cervical cancer
     
  • Surveillance with Pap screening by physicians like you has led to a significant decline in cervical cancer deaths (30% decline between 1991 and 2007)1
     
  • The incidence of cervical cancer has continuously declined by approximately 2.5% per year over the past 2 decades1

Number of cervical cancer cases and deaths per 100,000 women

With the addition of co-testing (Pap and HPV) to 2012 cervical cancer screening guidelines, the rate of newly diagnosed cases has continued to decline.


The quality of the Pap matters

At Quest Diagnostics, the standards for Pap testing go above and beyond. We are committed to maintaining high laboratory standards that help you diagnose with confidence.

Employees using microscopes

  • Quest Diagnostics drove adoption of liquid-based cytology (LBC) in the 1990s, conducting the largest single-facility LBC study in the US to confirm the test’s increased sensitivity1
     
  • Because the accuracy of the Pap test depends on the quality of the analysis, our quality control program results in random and targeted rescreening of all normal Paps at nearly twice the minimum federal requirement for labs
     
  • Our expert Gynecologic Pathology staff has seen more high-grade lesions (HSIL), as well as rare and unusual cases, than most pathologists
     
  • All abnormal Paps are reviewed by 1 or more pathologists, who then report back to the original reviewer with further consultation as needed

 

References:

1. National Cancer Institute. SEER stat fact sheets: cervix uteri cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed July 31, 2015.

2. Quest Diagnostics. Data on file.